Skip to Main Content

Celgene (CELG) is the only large-cap biotech that provides investors with long-range financial guidance. It’s a risky strategy that pays off well when the business is humming but can backfire quickly if plans run off the rails.

The latter just happened to Celgene. A weaker outlook for several of its drugs plus one big pipeline blowup forced Celgene to make a deep cut in its 2020 revenue guidance on Thursday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.